Xencor (XNCR) Cash & Current Investments (2013 - 2026)
Xencor (XNCR) reported Cash & Current Investments of $74.7 million for Q1 2026, down 82.23% year-over-year from $420.7 million in Q1 2025, and down 55.13% quarter-over-quarter from $166.6 million in Q4 2025.
Xencor (XNCR) Cash & Current Investments (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Cash & Current Investments data on file, last reported at $74.7 million in Q1 2026.
- Cash & Current Investments for Q1 2026 came in at $74.7 million, down 82.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $74.7 million (down 82.23% YoY), and the FY2025 annual result was $166.6 million, up 87.58% from the prior year.
- Cash & Current Investments retreated to $74.7 million in Q1 2026 per XNCR's latest filing, from $166.6 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $580.6 million in Q4 2022 and troughed at $74.7 million in Q2 2023.
- A 5-year average of $324.1 million and a median of $403.4 million in 2025 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2023 and 2024: Cash & Current Investments sank 84.6% in 2023, then surged 542.71% in 2024.
- A 5-year view of Cash & Current Investments shows it stood at $580.6 million in 2022, then dropped by 5.01% to $551.5 million in 2023, then tumbled by 83.9% to $88.8 million in 2024, then soared by 87.58% to $166.6 million in 2025, then tumbled by 55.13% to $74.7 million in 2026.
- Business Quant data shows XNCR's Cash & Current Investments at $74.7 million in Q1 2026, $166.6 million in Q4 2025, and $386.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | 74.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.74 Mn |
| Dec 31, 2025 | 166.58 Mn |
| Sep 30, 2025 | 386.78 Mn |
| Jun 30, 2025 | 403.43 Mn |
| Mar 31, 2025 | 420.70 Mn |
| Dec 31, 2024 | 88.80 Mn |
| Sep 30, 2024 | 464.07 Mn |
| Jun 30, 2024 | 480.14 Mn |
| Mar 31, 2024 | 75.57 Mn |
| Dec 31, 2023 | 551.52 Mn |
| Sep 30, 2023 | 465.56 Mn |
| Jun 30, 2023 | 74.71 Mn |
| Mar 31, 2023 | 112.10 Mn |
| Dec 31, 2022 | 580.63 Mn |
| Sep 30, 2022 | 568.05 Mn |
| Jun 30, 2022 | 485.03 Mn |
| Mar 31, 2022 | 111.70 Mn |
| Dec 31, 2021 | 180.34 Mn |
| Sep 30, 2021 | 88.78 Mn |
| Jun 30, 2021 | 161.07 Mn |